Your browser doesn't support javascript.
loading
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.
Meulendijks, Didier; Henricks, Linda M; Sonke, Gabe S; Deenen, Maarten J; Froehlich, Tanja K; Amstutz, Ursula; Largiadèr, Carlo R; Jennings, Barbara A; Marinaki, Anthony M; Sanderson, Jeremy D; Kleibl, Zdenek; Kleiblova, Petra; Schwab, Matthias; Zanger, Ulrich M; Palles, Claire; Tomlinson, Ian; Gross, Eva; van Kuilenburg, André B P; Punt, Cornelis J A; Koopman, Miriam; Beijnen, Jos H; Cats, Annemieke; Schellens, Jan H M.
Afiliación
  • Meulendijks D; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Henricks LM; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Sonke GS; Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Deenen MJ; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Froehlich TK; University Institute of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
  • Amstutz U; University Institute of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
  • Largiadèr CR; University Institute of Clinical Chemistry, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland.
  • Jennings BA; Norwich Medical School, University of East Anglia, Norwich, UK.
  • Marinaki AM; Purine Research Laboratory, St Thomas' Hospital, London, UK.
  • Sanderson JD; Department of Gastroenterology, St Thomas' Hospital, London, UK.
  • Kleibl Z; Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
  • Kleiblova P; Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
  • Schwab M; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; Department of Clinical Pharmacology, University Hospital Tuebingen, Tuebingen, Germany.
  • Zanger UM; Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany; University of Tuebingen, Tuebingen, Germany.
  • Palles C; Molecular and Population Genetics Laboratory and Oxford NIHR Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Tomlinson I; Molecular and Population Genetics Laboratory and Oxford NIHR Biomedical Research Centre, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.
  • Gross E; Department of Gynecology and Obstetrics, Technische Universität München, Munich, Germany.
  • van Kuilenburg AB; Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
  • Punt CJ; Department of Medical Oncology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands.
  • Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Beijnen JH; Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, Netherlands.
  • Cats A; Department of Gastroenterology and Hepatology, Netherlands Cancer Institute, Amsterdam, Netherlands.
  • Schellens JH; Department of Clinical Pharmacology, Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands; Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utr
Lancet Oncol ; 16(16): 1639-50, 2015 Dec.
Article en En | MEDLINE | ID: mdl-26603945
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Polimorfismo Genético / Dihidrouracilo Deshidrogenasa (NADP) / Enfermedades Gastrointestinales / Enfermedades Hematológicas / Neoplasias / Antimetabolitos Antineoplásicos Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Polimorfismo Genético / Dihidrouracilo Deshidrogenasa (NADP) / Enfermedades Gastrointestinales / Enfermedades Hematológicas / Neoplasias / Antimetabolitos Antineoplásicos Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2015 Tipo del documento: Article País de afiliación: Países Bajos